Key Takeaways Novo Nordisk won EU approval to update Rybelsus' label with cardiovascular benefits.The SOUL study showed Rybelsus cut the risk of major cardiovascular events by 14% versus placebo.Rybelsus is now the only oral GLP-1 in the EU for T2D with a proven cardiovascular benefit.Novo Nordisk (NVO) has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus (oral semaglutide), to reflect cardiovascular benefits demonstrated in the phase IIIb SOUL study. The ...